<DOC>
	<DOCNO>NCT00904345</DOCNO>
	<brief_summary>This single-arm , phase II trial characterize clinical outcome standard care , cetuximab concurrent radiation , special population ( head neck cancer patient tolerate concurrent chemoradiotherapy due advanced age , poor performance status concurrent illness ) , determine biomarker response load dose cetuximab predictive outcome .</brief_summary>
	<brief_title>Study Radiation ( RT ) Concurrent With Cetuximab Patients With Advanced Head Neck Squamous Cell Carcinoma ( SCC )</brief_title>
	<detailed_description>Primary Objective 1 : Determine change tumor EGFR , pEGFR , downstream signal novel phosphoprotein follow load dose cetuximab patient poor candidate chemoradiation ( age =70 year significant co-morbidities ) therefore treat cetuximab radiation . Primary Objective 2 : Characterize clinical outcome , include local recurrence , progression-free survival overall survival patient , correlate clinical outcome change tumor EGFR , pEGFR , downstream signaling , novel phosphoprotein . Primary Objective 3 : Describe toxicity , particular mucositis/dysphagia , regimen . Secondary Objective 1 : Conduct normal mucosa EGFR assessment comparison tumor sample . Secondary Objective 2 : Correlate HPV presence titer p53 status clinical outcome .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients must pathologicallyconfirmed , previously untreated , clinically accessible ( without general anesthesia ) locally advance squamous cell carcinoma larynx , hypopharynx , oropharynx , oral cavity , nonresectable head neck squamous cell carcinoma skin . Patients limit : ≥ 70 year age , OR comorbidities preclude treatment standard platinumbased chemotherapy , determine treat physician , OR KPS ≤ 80 , OR Creatinine clearance &lt; 30 cc/min Laboratory criterion : WBC &gt; 3500/ul Granulocyte &gt; 1500/ul Platelet count &gt; 100,000/ul Total Bilirubin &lt; 1.5 X ULN AST ALT &lt; 2.5 X ULN Patients must give document informed consent participate study . Prior head neck malignancy , history prior nonhead neck malignancy within past 3 year ( exclude skin cancer early stage treat prostate cancer ) . Prior head neck radiation chemotherapy . Documented evidence distant metastasis . Patients nasopharyngeal carcinoma . Any medical psychiatric illness , , opinion principal investigator , would compromise patient 's ability tolerate treatment . Patients psychiatric/social situation would limit compliance study requirement eligible . Patients prior antiepidermal growthfactor receptor antibody therapy ( antibody small molecule ) . Patients reside prison .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>SCC Head Neck Cancer</keyword>
</DOC>